FIELD: chemistry.
SUBSTANCE: disclosed is a compound of formula II
where: X1 - CR7; X2 is selected from a group comprising N and CR10; each of R1, R3 and R4 is independently selected from a group comprising -H, halogens, substituted or unsubstituted alkyls with 1–8 carbon atoms, unsubstituted cycloalkyls with 3–6 carbon atoms, -C(O)NRARB, -ORA, -NRARB, -S(O)2RA, unsubstituted phenyl and substituted or unsubstituted oxetane or piperazine; R2 is independently selected from a group comprising -H, halogens, substituted or unsubstituted alkyls with 1–8 carbon atoms, unsubstituted cycloalkyls with 3–6 carbon atoms, -C(O)NRARB, -ORA, -NRARB, -S(O)2RA, substituted or unsubstituted phenyl and unsubstituted oxetane or piperazine; each of R7, R10 and R11 is independently selected from a group comprising -H and unsubstituted alkyls with 1–8 carbon atoms; each of R5 and R6 is independently selected from a group comprising -H, halogens and unsubstituted alkyls with 1–8 carbon atoms; each of R8 and R9 is independently selected from a group comprising -H and halogens; each of RA and RB in the presence of independently selected from a group comprising -H, halogens, substituted or unsubstituted alkyls with 1–8 carbon atoms, substituted or unsubstituted cycloalkyls with 3–6 carbon atoms; in those cases, when for X1 N is selected, as X2 CH is selected, and as each of radicals R1, R2, R3, R4, R8, R9 and R11 selected is hydrogen, substitutes for substituted alkyl are independently selected from amino, alkylamino, alkoxy, alkylsulfanyl, oxo (= O), halo, acyl, nitro, hydroxyl, cyano, thione (= S) and imino; substitutes for substituted cycloalkyl are independently selected from halogen and unsubstituted alkyl with 1–8 carbon atoms, or pharmaceutically acceptable salt for inhibition of tubulin activity.
EFFECT: disclosed are antimitotic amides for treating cancer and proliferative diseases.
40 cl, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
SELECTIVE ESTROGEN RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2734501C2 |
N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
COMPLEXES | 2015 |
|
RU2684934C2 |
PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
SPIROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2781639C2 |
HALOGENALLILAMINE DERIVATIVES AND THEIR APPLICATIONS | 2020 |
|
RU2793850C2 |
DERIVATIVES OF BETA-AMINO ACID NITRILES | 2001 |
|
RU2245871C2 |
CDK8/19 INHIBITORS | 2018 |
|
RU2761824C2 |
NOVEL CYCLOSPORIN DERIVATIVES FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS | 2011 |
|
RU2601742C2 |
DERIVATIVES OF 4-PIPERIDINYLALKYLAMINE AND PHARMACEUTICAL COMPOSITION POSSESSING ANTAGONISTIC AFFECT ON MUSCARINIC RECEPTOR | 2002 |
|
RU2300524C2 |
Authors
Dates
2020-02-04—Published
2015-02-20—Filed